Flagship Harbor Advisors’s NovoCure NVCR Stock Holding History

Flagship Harbor Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-85	Closed	-$1.1K	–	1682
2025 Q4	$1.1K	Buy	+85	New	+$1.09K	﹤0.01%	1926
2020 Q4	–	Sell	-70	Closed	-$7K	–	1323
2020 Q3	$7K	Hold	70	–	–	﹤0.01%	1436
2020 Q2	$4K	Hold	70	–	–	﹤0.01%	1657
2020 Q1	$5K	Hold	70	–	–	﹤0.01%	1420
2019 Q4	$6K	Hold	70	–	–	﹤0.01%	1484
2019 Q3	$5K	Buy	+70	New	+$5.6K	﹤0.01%	1497

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Flagship Harbor Advisors's NVCR Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 85 shares — an estimated $1.1K sold.

Flagship Harbor Advisors first reported a position in NVCR in Q3 2019 and held it in 6 quarters. The position peaked at $7K in Q3 2020. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Flagship Harbor Advisors reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
Flagship Harbor Advisors sold 85 NovoCure shares in Q1 2026, an estimated $1.1K.
Flagship Harbor Advisors first reported a position in NovoCure in Q3 2019 and held it in 6 quarters.
Flagship Harbor Advisors's NovoCure position peaked at $7K in Q3 2020.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.